We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
There is prior research to support the use of statins in patients with viral or bacterial pneumonia, which suggested their potential to combat COVID-19 by positive immuno-modulatory, anti-inflammatory, and anti-coagulant effects. This article outlines what is known from Chinese cohorts regarding the use of statins in COVID-19 and current issues including adverse side effects and drug–drug interactions.
There are good data to suggest continuation of statin therapy for patients with active prescriptions, and the authors suggest initiation of robust clinical research to determine if there is a clinical benefit for COVID-19 patients.
– Kolene Bailey, MD
This abstract is available on the publisher's site.
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has spread around the world like a wildfire in the past six months. With a high infectivity rate, the disease has already accounted for nearly ten million cases worldwide with deaths accounting to more than a half a million1. A lack of specific drug therapy has prompted a global race to develop or search for newer therapies as well as repurposing the older drugs such as hydroxychloroquine and azithromycin. As better insight has been gained on the disease pathophysiology, focus has now shifted to the use of anti-virals (Remdesivir), anti-inflammatory and immunosuppressive agents such as tocilizumab. Repurposing of old drugs developed for other diseases has an advantage that a detailed information exists regarding the pharmacological and safety profile in humans thus being cost-effective and a time saving strategy2. One such class of repurposed drugs which can be of benefit in COVID-19 infection are the statins.